Cell and gene therapies have reached a turning point in their advancement. After more than a decade confined to relapsed or refractory hematologic cancers, the modality is now demonstrating early phase clinical proof-of-concept in immune-mediated inflammatory diseases, backed by a development pipeline that exceeded 100 registered clinical trials through 2025. Conditions such as systemic lupus erythematosus, multiple sclerosis, rheumatoid arthritis, myasthenia gravis, and stiff-person syndrome affect hundreds of millions of people worldwide, yet current treatments remain largely suppressive, leaving patients exposed to flares, organ damage, and accumulating long-term toxicity. Emerging clinical evidence now validates the possibility of durable, drug-free remission through immune system reset. Translating that promise into executed programs demands operational capability that most development teams must deliberately build.
Read our white paper to learn more about:
- How emerging clinical data across immune-mediated conditions are reshaping clinical development, and why early safety profiles are different from those carried over from oncology
- The four-domain Immunology CAR T Site Readiness Framework that assesses infrastructure, clinical capability, regulatory readiness, and patient access
- How enrollment heterogeneity, multi-layered regulatory oversight, and a time-sensitive autologous supply chain from leukapheresis to infusion shape the operational planning required to bring CAR T programs successfully to patients